Pathos AI signs two cancer deals with Alphamab and AZ
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
Newsletters and Deep Dive digital magazine
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
Healthcare organisations can’t afford to ignore agentic AI, but they also can’t afford to deploy it without the infrastructure to use it responsibly.
Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.
Digital health cannot succeed without infrastructure that supports it at every level.
The creation of a Single Patient Record (SPR) is one of the most significant reforms to health data in a generation.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks